Medicine

Early-life obesity may reprogram T cells and weaken vaccine immunity

A University of Pennsylvania team traced the defect to suppressed activity of the A20 gene in mice and found a similar shortage of circulating T follicular helper cells in five patients who carry one copy of it

By Giovanni Sapere
3 min read

ShareLinkedInFacebookX

Early-life obesity may reprogram T cells and weaken vaccine immunity
AI-generated cover image

Young mice exposed to a high-fat diet in the womb and after birth make fewer T follicular helper cells, the immune cells that organise antibody responses, researchers at the Perelman School of Medicine at the University of Pennsylvania report. The team traced the fault to a gene for the enzyme A20 and found a matching shortage of those cells in five patients who lack one working copy of the gene. The study appears in Nature Immunology and describes no patent filing.

A mouse model shows fewer antibody organisers

The experiment used a mouse model of juvenile obesity. The animals carried a deficiency in the immune cell subtypes that normally cooperate to drive antibody responses against viral infections and to establish long-term antibody immunity, the study reports. Their responses to vaccine exposures were weaker as well. MedicalXpress

The defect sits at a specific step. Immature T cells were less able to mature into T follicular helper (TFH) cells, which organise antibody production, while more inflammatory T cell subtypes appeared in their place. The paper notes that childhood obesity is already linked to serious illness from respiratory viruses such as flu and COVID, and that maternal overweight before and during pregnancy raises the risk of childhood obesity. What had been unclear was the biology connecting the two. MedicalXpress

“Maternal and early postnatal diet create an environmental signal that can durably reprogram developing T cells”

— Jorge Henao-Mejia, professor of pathology and laboratory medicine at the University of Pennsylvania

“The findings reveal a critical, early-life window in which a high-fat diet can negatively reprogram the immune system and leave children vulnerable to infections”

— Sarah Henrickson, assistant professor of pediatrics at the University of Pennsylvania

A20 activity is suppressed in immature T cells

The proximate cause, the authors found, is a reprogramming of immature T cells in which the activity of a gene for a key enzyme called A20 is suppressed. The change did not fade quickly, which is why the team describes the early-life period as decisive. MedicalXpress

Read also on The Patent: Revolutionary Discovery: Hubble Telescope Unveils Water Vapor on Distant Mini-Exoplanet GJ 9827d

"Maternal and early postnatal diet create an environmental signal that can durably reprogram developing T cells," said co-senior author Jorge Henao-Mejia, professor of pathology and laboratory medicine at Penn. The paper lists Michaël F. Michieletto as first author and carries the DOI 10.1038/s41590-026-02700-6. MedicalXpress

Five patients show the same TFH shortfall

To connect the mouse work to people, the researchers examined immune cells from five patients with a rare genetic condition in which one copy of the A20 gene is lost. Compared with matched children and adults who had normal A20 levels, the patients had a marked shortage of circulating TFH cells, closely resembling the pattern in the obese juvenile mice. MedicalXpress

That comparison supports the mouse finding but comes with a limit: five patients is a small group, and the main experimental evidence is from animals. "The findings reveal a critical, early-life window in which a high-fat diet can negatively reprogram the immune system and leave children vulnerable to infections," said co-senior author Sarah Henrickson, assistant professor of pediatrics. The work was published on 16 November 2026 in Nature Immunology and was peer reviewed. MedicalXpress

No patent filing, but a drug target to test

Identifying A20 as the trigger also points to a possible treatment: a drug designed around the enzyme might reverse the immune impairment in people who carry the defect, the authors suggest. That is a hypothesis. The source describes no compound, no clinical trial and no patent application. MedicalXpress

For readers who follow intellectual property in medicine, the omission is part of the story. The study is academic research from a university medical school, published in a journal. Neither the paper nor the university's release mentions a patent filing, a licence or a commercial partner. The source names no innovation that has been claimed as an invention. MedicalXpress

AI-assisted article